Octreotid Bendalis (Octreotide)

Octreotide, the active ingredient in Octreotid Bendalis, is a somatostatin analog presented as a sterile injectable solution for subcutaneous or intravenous use. It is employed to control hormone‑secreting tumors and related endocrine disorders. GNH USA supplies Octreotid Bendalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Octreotide acts on neuroendocrine pathways to regulate excessive hormone secretion. - Acromegaly: lowers growth hormone and IGF‑1 levels, helping to control disease activity. - Carcinoid syndrome: reduces flushing and diarrhea by inhibiting serotonin release. - VIPoma: controls severe watery diarrhea and electrolyte loss through vasoactive intestinal peptide suppression. - Neuroendocrine tumors: slows tumor‑related hormone production and may limit tumor growth.

Octreotide may cause a range of adverse reactions.

Common Side Effects: - Abdominal pain or discomfort - Nausea and vomiting - Diarrhea or constipation - Gallstone formation - Injection site erythema or bruising - Hyperglycemia or altered glucose tolerance

Serious or Rare Side Effects: - Acute pancreatitis - Severe hypoglycemia, especially in diabetic patients - Cardiac arrhythmias or conduction disturbances - Anaphylactic or severe allergic reactions - Biliary colic or cholecystitis related to gallstones - Severe infection at injection site

Octreotide requires careful monitoring in several clinical situations. - Renal impairment: monitor renal function and adjust therapy as needed. - Gallbladder disease: assess for gallstone formation and biliary complications. - Diabetes mellitus: regularly check blood glucose levels for hyper‑ or hypoglycemia. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Concomitant medications: review all drugs for possible interactions before initiating therapy. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide can influence or be influenced by other medicines.

Major Interactions (Avoid): - Cyclosporine: may increase octreotide plasma concentrations, raising risk of adverse effects. - Other somatostatin analogs: additive hormonal suppression can lead to severe hypoglycemia or gallbladder issues.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycemics: octreotide may mask hypoglycemia symptoms; adjust glucose monitoring. - Diazoxide and glucagon: may reduce octreotide efficacy in controlling hormone excess. - Certain antibiotics (e.g., erythromycin): can alter gut flora and affect hormone metabolism, requiring observation.